NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
28 5월 2024 - 9:05PM
Business Wire
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, will showcase its versatile lung solution
and its COMPASS® Hematopathology Services portfolio at the American
Society of Clinical Oncology (ASCO) conference in Chicago, May
31–June 4 (booth #31093).
“With cancer cases on the rise, we’ve seen tremendous growth in
FDA-approved targeted therapies and immunotherapies, making proper
test selection critical for precision medicine-based patient
management,” said Chris Smith, CEO of NeoGenomics. “Our wide
breadth of testing solutions represents a significant milestone in
our mission to empower clinicians with the tools needed to deliver
the best possible care to patients, whether it’s early or advanced
stage, and whether there is tissue or not.”
Recognizing the benefits of concurrent testing, as supported by
the National Comprehensive Cancer Network (NCCN) guidelines,
NeoGenomics’ comprehensive lung offering allows for complementary
tissue and liquid biopsy testing. The test portfolio provides a
comprehensive approach to diagnosis, therapy selection, prognosis,
and clinical trial options tailored to each patient's unique needs,
addressing the disease’s complexities:
- Early Stage NSCLC is the industry's first therapy
selection panel for early-stage non-small cell lung cancer (NSCLC),
delivering actionable insights within seven days.
- DNA & RNA Lung is a 50-gene NGS panel enriched with
MSI and TMB analysis to facilitate precise therapy selection and
clinical trial matching.
- InvisionFirst® Lung is a liquid biopsy assay that
detects 37 genes crucial to NSCLC treatment. It surpasses
tissue-based assays in actionable alterations and is available for
patients without viable tissue samples.
- Comprehensive™ Solid Tumor test analyzes 517 genes via
DNA and RNA next-generation sequencing, providing clinicians with a
complementary understanding of the patient's cancer profile to
guide optimal treatment options.
NeoGenomics will also feature COMPASS, a suite of single-order
sample-to-diagnosis services for hematological malignancies. With
over 100 subtypes of leukemias, lymphomas, and myelomas, reaching a
definitive diagnosis requires the time and expertise to manage
ever-evolving clinical guidelines and testing criteria. COMPASS
provides an all-in-one assessment with actionable diagnostic and
prognostic information unique to the patient.
In addition to highlighting these solutions, NeoGenomics will
present a poster, titled “Comparative analysis of actionable gene
reporting in targeted panels versus comprehensive NGS testing for
solid tumor samples,” during the Quality Care/Health Services
Research poster session on June 3, 2024 (Abstract #11185; Poster
Board #380).
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus in the world for physicians to help
them diagnose and treat cancer. The Company's Pharma Services
Division serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, Fla., NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
Forward-Looking Statements
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “plan,” “could,” “would,”
“may,” “will,” “believe,” “estimate,” “forecast,” “goal,”
“project,” “guidance,” “plan,” “potential” and other words of
similar meaning, although not all forward-looking statements
include these words. This press release includes forward-looking
statements. These forward-looking statements address various
matters, including statements regarding improving operational
efficiency, returning to profitable growth and its ongoing
executive recruitment process. Each forward-looking statement
contained in this press release is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, the Company's ability to
identify and implement appropriate financial and operational
initiatives to improve performance, to identify and recruit
executive candidates, to continue gaining new customers, offer new
types of tests, integrate its acquisitions and otherwise implement
its business plan, and the risks identified under the heading "Risk
Factors" contained in the Company's Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and the Company's other filings with
the Securities and Exchange Commission.
We caution investors not to place undue reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this document (unless another date is
indicated), and we undertake no obligation to update or revise any
of these statements. Our business is subject to substantial risks
and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240528418788/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
NeoGenomics (NASDAQ:NEO)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024